A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enzalutamide (Primary) ; Radium 223 chloride (Primary)
Indications Adenocarcinoma; Bone metastases; Prostate cancer
Focus Therapeutic Use
Acronyms PEACE III

Most Recent Events

01 Mar 2025 Results of interim analysis comparing radium-223 (223Ra) combined with enzalutamide for first-line mCPRC to enzalutamide alone, published in the European Urology
04 Apr 2024 Planned End Date changed from 1 Dec 2025 to 1 Dec 2028.
29 Mar 2023 Planned primary completion date changed from 1 Dec 2024 to 1 Mar 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight